Premium
Drug therapy of frontotemporal dementia
Author(s) -
Allain Hervé,
BentuéFerrer Danièle,
Tribut Olivier,
Mérienne Marc,
Belliard Serge
Publication year - 2003
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.472
Subject(s) - frontotemporal dementia , dementia , neurochemical , parkinsonism , serotonergic , neuroscience , psychology , medicine , psychiatry , disease , serotonin , receptor
Frontal lobe dementia, or more generally frontotemporal dementia (FTD), includes several clinical entities and, although highly prevalent, lacks any codified therapeutic strategy. The present review is an attempt to depict the main neurochemical correlates of FTD and, as a consequence, to propose the most sound targets for symptomatic drugs. Large scale double‐blind controlled clinical trials should be carried out to test any hypothesis: serotonergic agents, glutamate neurotransmission enhancers, monoamine oxidase inhibitors. The recent discovery of tau gene mutations in FTD with Parkinsonism linked to chromosome 17 has reinforced the direct role attributed to abnormal tau proteins (hyperphosphorylation) and thus raised the possibility to target specifically these processes by drugs (aetiopathogenic compounds). Copyright © 2003 John Wiley & Sons, Ltd.